Carbidopa Anhydrous

Carbidopa Anhydrous

SCHEMBL35084

C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DDC

The experimentally established mechanism targets of Carbidopa Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 1.00
KDM4E B2RXH2 5/20 1.00
MAPT P10636 5/20 1.00
TDP1 Q9NUW8 4/20 1.00
HPGD P15428 4/20 1.00
ALOX15 P16050 4/20 1.00
POLB P06746 3/20 1.00
ALDH1A1 P00352 3/20 1.00
CYP1A2 P05177 3/20 1.00
LMNA P02545 3/20 1.00
THPO P40225 3/20 1.00
CYP3A4 P08684 2/20 1.00
MAPK1 P28482 2/20 1.00
ALOX12 P18054 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
BLM P54132 4/20 0.65
GAA P10253 2/20 0.65
APEX1 P27695 2/20 0.65
PMP22 Q01453 2/20 0.65
USP2 O75604 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbidopa Anhydrous SCHEMBL29392554 1.00 HSD17B10 (1.00) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL2688295 1.00 HSD17B10 (1.00) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL8407333 1.00 HSD17B10 (1.00) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL5051647 1.00 HSD17B10 (1.00) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL30803536 1.00 HSD17B10 (1.00) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL1211698 0.98 KDM4E (0.97) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL1217887 0.98 HSD17B10 (0.97) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL29658622 0.98 HSD17B10 (0.97) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL9064019 0.98 HSD17B10 (0.97) HSD17B10KDM4EMAPTTDP1HPGD
Carbidopa Anhydrous SCHEMBL19475325 0.98 HSD17B10 (0.97) HSD17B10KDM4EMAPTTDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 29223 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4389173-B1 DEVICE FOR SUBCUTANEOUS DELIVERY OF FLUID MEDICAMENT NEURODERM LTD (IL) 2026-05-27 EP claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
WO-2026106939-A1 IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION VANDERBILT UNIVERSITY (US) 2026-05-21 WO claimed
EP-3782614-B1 MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF IMPAX LABORATORIES LLC (US) 2026-05-20 EP claimed
WO-2026102000-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY VOYAGER THERAPEUTICS, INC. (US) 2026-05-15 WO claimed
WO-2026099869-A1 DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF PARKINSON'S DISEASE REMEPY HEALTH LTD (IL) 2026-05-15 WO claimed
US-20260130880-A1 DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF PARKINSONS DISEASE REMEPY HEALTH LTD (IL) 2026-05-14 US claimed
US-20260131140-A1 MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION VANDERBILT UNIV (US) 2026-05-14 US claimed
US-20260130881-A1 SUSTAINED RELEASE DEVICE CONTENTS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER DISORDERS BUSHARA KHALAFALLA (US) 2026-05-14 US claimed
EP-4740962-A1 PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION Shanghai WD Pharmaceutical Co., Ltd (CN) 2026-05-13 EP claimed
US-4421767-A 3-(HYDROXYPHENYL)-2-AMINO-3-BUTENOIC ACID OR DERIVATIVE MERRELL TORAUDE ET COMPAGNIE (FR) 1983-12-20 US claimed
US-4413012-A Method for treating depression MERRELL TORAUDE ET COMPAGNIE (FR) 1983-11-01 US claimed
EP-0083032-A2 Rectally administrable suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1983-07-06 EP claimed
US-4389415-A ALPHA-METHYL-P-TYROSINE, HYDRAZINO PHENYLPROPIONIC ACID MERCK & CO., INC. (US) 1983-06-21 US claimed
EP-0066518-A2 Compounds and methods for treating depression MERRELL DOW FRANCE ET CIE (FR) 1982-12-08 EP claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 EP claimed
US-4329356-A Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane ELI LILLY AND COMPANY (US) 1982-05-11 US claimed
US-4313956-A Novel sypathomimetic amine prodrugs INTERX RESEARCH CORP. (US) 1982-02-02 US claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed